StockData

Aspire-Lakewood vs Lexaria Bioscience

ASBP and LEXX side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How ASBP and LEXX compare

Lexaria Bioscience is the larger company, worth 8.9 times as much as Aspire-Lakewood ($104M against $11.6M).

Lexaria Bioscience keeps more of each dollar of sales as profit, with a net margin of −3986% compared with −11314% at Aspire-Lakewood.

Lexaria Bioscience scores higher on the StockData Score (8 against 2 for Aspire-Lakewood), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricASBPLEXX
Size and price
Market cap$11.6M$104M
Share price$8.30$4.18
Change, 1 year95.8%−73.7%
Change, 5 years–−94.8%
Beta (5Y)–0.13
Employees–134
StockData Score
Total score28 (better)
Valuation score1 (better)0
Growth score02 (better)
Performance score00
Health score16 (better)
Dividend score00
Valuation
P/S119× (better)534×
P/B1.0× (better)21.9×
FCF yield–−7.2%
Growth
Revenue growth (TTM)–−68.5%
Revenue growth, 5Y average–17.5%
Profitability
Gross margin−25.0%100% (better)
Operating margin−7495%−3973% (better)
Net margin−11314%−3986% (better)
FCF margin–−3849%
Return on equity−1032%−150% (better)
Return on invested capital–−602%
Financial health
Debt / equity–0.00
Interest coverage−0.8×–
Current ratio7.9910.60 (better)
Altman Z-score−0.10117.82 (better)
Piotroski F-score3 (better)2
Dividends and buybacks
Buyback yield–−6.3%
Shareholder yield0.00% (better)−6.3%
Ownership
Held by insiders1.4%3.0%
Short interest, % of float–0.90%

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.